Live Radio

CONFERENCE PRESENTATIONS

    (Last Updated : November 15, 2004)

12-14 January 2004

    WHO Workshop: WHO Independent Evaluation of the Safety and Efficacy of HIV-1 Immunogen (REMUNE)
    Bangkok, Thailand

    AGENDA

6-11 January 2004

21 October 2003

24 March 2003

    Geneva Meeting on REMUNE® (Thailand) – Participated by REMUNE® Thai Investigators and World Health Organization (WHO) Experts WHO, Geneva, Switzerland

  • Phase II Clinical Trials Results
    presented by Dr. Vina Churdboonchart
     
  • Extended Phase II Clinical Trial Results
    presented by Dr. Wisut Sukeepaisarncharoen
     
  • Mutation and Drug Resistant
    presented by Dr. Wasun Chantratita
     
  • Good Laboratory Practice in the CD4+ cell Evaluation
    presented by Dr. Worachart Sirawaraporn
     
  • Good Clinical Practice adapted by Thailand Phase II Study
    presented by Dr. Boonsri Israngkura Na Ayudthaya
     
  • Statistical Analysis for CD4+cell as Surrogate Markers
    presented by Asst. Prof. Chaweewon Boonshuyar and Dr. Wisut Sukeepaisarncharoen
     
  • Immune-based Therapy and Efficacy Endpoints
    presented by Dr. Verapol Chandeying and commented by Prof. Emer. Dr. Natth Bhamarapravati
     
  • Ethical Issues on Vaccine Trials
    presented by Dr. Sang-a-roon Kulpradist
     
  • Certificate of Free Sale and Thai FDA Registration of a New Drug
    presented by Prof. Vanida Chitman
     

27 July – 01 August 2002

    2002 FASEB Summer Research Conference: Therapeutic and Preventive AIDS Vaccine
    Tucson, Arizona, USA

  • Poster and Oral Presentation
    HIV-1 Genotypic Drug Resistance in REMUNE® and ART-Treated Subjects in Thailand
    by Dr. Wasun Chantratita
     
  • Poster and Oral Presentation
    Long-Term REMUNE® Therapy in Extended Phase II Thailand Study at Week 132
    by Dr. Wisut Sukeepaisarcharoen
     
  • Oral Presentation
    REMUNE® Clinical Trials in Thailand (Years 1996-2002)
    by Dr. Vina Churdboonchart
     

7-12 July 2002

    XIV International AIDS Conference
    Barcelona, Spain

  • Poster Presentation Poster No. MoPeA3039
    The effect of long-term REMUNE® monotherapy on CD4+ cells
     

23-26 June 2002

    Therapeutic Vaccines Against HIV and Cancers
    Centre “Les Pensieres”, Veyrier-du-Lac, France

  • Poster Presentation
    Results of HIV-1 Genotypic drug-resistance testing done in REMUNE® treated subjects in Thailand
     

5-11 April 2002

    HIV-1 Protection and Control by Vaccination
    Keystone Resort, Keystone, Colorado, USA

  • Poster Presentation
    Effectiveness of REMUNE® monotherapy at Week 144
     

23-27 July 2001

    An International Conference on “HIV Vaccines - An Annual Update 2001”
    Siam City Hotel, Bangkok, Thailand

  • REMUNE® Clinical Trials in the USA
    presented by Dr. Ronald B. Moss
     
  • European (Spain) Study STIR -2102
    presented by Dr. Fernandez-Cruz
     
  • REMUNE® Clinical Trials in Thailand
    presented by Dr. Vina Churdboonchart
     
  • REMUNE® and Genotypic Assay
    presented by Dr. Wasun Chantratita
     
  • REMUNE® Monotherapy and CD4+ Cells
    Presented by Dr. Wisut Sukeepaisarncharoen
     

08-11 July 2001

    The 1st IAS Conference on HIV Pathogenesis and Treatment
    Sheraton Hotel and Towers Convention Center, Buenos Aires, Argentina

  • Latebreaker Abstract No. LB-P18
    Results of long term treatment with HIV-1 Immunogen (REMUNE®) as
    mono immune-based therapy with results from drug resistance testing

    W. Chantratita, V. Churdboonchart, W. Sukeepaisarncharoen, W. Sirawaraporn, S. Kulpradist, B. Israngkura Na Ayudhtaya, V. Chandeying, S. Rugpao,    D. Carlo, and RB Moss
     
  • Abstract No. 662
    Results at week 96 of an open label follow up study of the effect of HIV-1 Immunogen (REMUNE®) in asymptomatic Type E HIV-1 infected Thai subjects not taking antiviral drugs (Submitted 27 Feb. 2001)

    W. Sukeepaisarncharoen V. Churdboonchart, S. Kulpradist, B. Israngkura
    Na Ayudhtaya, V. Chandeying, S. Rugpao, W. Sirawaraporn, D. Carlo, and 
    RB Moss
     

14-16 June 2001

    XI Symposium on HIV Infection
    Neptune International Congress Center, Toulon, France
     

  • Abstract Presentation
    Study of the long term effects of REMUNE® in a cohort of asymptomatic Type E HIV-1 infected Thai subjects not taking antiviral drugs over two years (D.5)

    S. Kulpradist, V. Churdboonchart, B. Israngkura Na Ayudhtaya, W. Sukeepaisarncharoen, S. Rugpao, V. Chandeying, and W. Sirawaraporn
     

9-14 July 2000

    13th International AIDS Conference (AIDS CONGREX 2000)
    International Convention Center, Durban, South Africa

  • Late Breaker
    Oral Presentation:
    Abstract No.: LbOr26
    Results of the follow-up study on 297 asymptomatic HIV-infected subjects previously enrolled in the Phase II double-blind, adjuvant-controlled trial of HIV-1 Immunogen (REMUNE®) in Thailand

    Churdboonchart, V., Sakondhavat, C., Israngkura Na Ayudhtaya, B., Kulpradist, S., Chandeying, V., Rugpao, S., Boonshuyar, C., Sukeepaisaencharoen, W., Sirawaraporn, W., and RB Moss

     
  • Poster Presentation
    Abstract No.ThPpB1483
    A Double-blind, Adjuvant-controlled Trial of HIV-1 Immunogen (REMUNE®) Mono Therapy in Asymptomatic, HIV-1 Infected Thai Subjects with CD4 Cell Counts > 300ul/mm3 (ThPpB1483)

    Churdboonchart, V., Sakondhavat, C., Israngkura Na Ayudhtaya, B., Kulpradist, S., Chandeying, V., Rugpao, S., Boonshuyar, C., Sukeepaisarncharoen, W., Sirawaraporn, W., Carlo, D.J. and RB Moss
     

28 June - 1 July 2000

    The First International Conference on Vaccine Development and Immunotherapy in HIV
    The Ritz-Carlton, Palm Beach, Florida, USA

  • Oral and Poster Presentation
    Results of a double-blind, adjuvant-controlled trial of HIV-1 Immunogen (REMUNE®) in asymptomatic HIV-1 infected Thai volunteers at Week 40 and 88

    Churdboonchart, V., Sakondhavat, C., Israngkura Na Ayudhtaya, B., Kulpradist, S., Chandeying, V., Rugpao, S., Boonshuyar, C., Sukeepaisaencharoen, W., Sirawaraporn, W., Carlo, D.J. and RB Moss
     

26-28 June 2000

    5th Asia-Pacific Congress of Medical Virology
    Radisson Bali Hotel, Denpasar-Bali, Indonesia

  • Abstract Presentation
    A double-blind, adjuvant-controlled trial of HIV-1 Immunogen (REMUNE®) in asymptomatic HIV-1 infected Thai volunteers at Week 40 and Week 88

    Churdboonchart, V., Sakondhavat, C., Israngkura Na Ayudhtaya, B., Kulpradist, S., Chandeying, V., Rugpao, S., Boonshuyar, C., Sukeepaisaencharoen, W., Sirawaraporn, W., and RB Moss
     

20-24 March 2000

    An International Conference on HIV Vaccines - An Annual Update - 2000
    Siam City Hotel, Bangkok, Thailand

  1. Immunotherapy Studies with REMUNE® in Thailand
    Churdboonchart, V., Sakondhavat, C., Israngkura Na Ayudhtaya, B., Kulpradist, S., Chandeying, V., Rugpao, S., Boonshuyar, C., Sukeepaisarncharoen, W. Sirawaraporn, W., Carlo, D.J. , and RB Moss
     
  2. Clinical Investigations of Subjects Treated with REMUNE®
    Sukeepaisarncharoen, W., Churdboonchart, V., Sakondhavat, C., Israngkura Na Ayudhtaya, B., Kulpradist, S., Boonshuyar, C., Sirawaraporn, W., Carlo, D.J. and RB Moss
     

02-05 March 2000

    The 2000 Palm Springs Symposium on HIV/AIDS (UC Regents)
    Palm Springs, CA, USA

  • A double-blind, adjuvant-controlled trial of HIV-1 Immunogen (REMUNE®) monotherapy in asymptomatic, HIV-1 infected Thai subjects with CD4 cell counts >300

    Churdboonchart, V., Sakondhavat, C., Israngkura Na Ayudhtaya, B., Kulpradist, S., Chandeying, V., Rugpao, S., Boonshuyar, C., Sukeepaisarncharoen, W., Sirawaraporn, W., and RB Moss.

21-24 February 2000

    WHO-UNAIDS VACCINE ADVISORY COMMITTEE MEETING
    Geneva, Switzerland

  • Oral Presentation with Dr. Ronald B. Moss of The Immune Response Corporation, 23 February 2000

    Churdboonchart, V.

425/129 Silom 5, Silom Road,
Bangkok 10500 Thailand
Telephone (662) 234-6390 - 91
Fax. No. (662) 636-6888
tac@trinitycorp.com

 

[PRODUCT] [RESEARCH   &  DEVELOPMENT] [CONFERENCE ABSTRACTS] [REMUNE  PUBLICATIONS  (THAILAND)]

[STT03]